The mechanism of action of cyclosporin A and FK506

doi:10.1016/0167-5699(92)90111-J

Immunology Today

Volume 13, Issue 4, 1992, Pages 136-142

Immunology Today

https://doi.org/10.1016/0167-5699(92)90111-J Get rights and content

Abstract

CsA and FK506 are powerful suppressors of the immune system, most notably of T cells. They act at a point in activation that lies between receptor ligation and the transcription of early genes. Here, Stuart Schreiber and Gerald Crabtree review recent findings that indicate CsA and FK506 operate as prodrugs: they bind endogenous intracellular receptors, the immunophilins, and the resulting complex targets the protein phosphatase, calcineurin, to exert the immunosuppressive effect.

References (80)

J Liu et al.
Cell
(1991)
M.W Harding et al.
J. Biol. Chem.
(1986)
C.L Verweij et al.
J. Biol. Chem.
(1990)
G Fischer et al.
Biochim. Biophys. Acta
(1985)
H.F Lodish et al.
J. Biol. Chem.
(1991)
D.A Hager et al.
Anal. Biochem.
(1980)
T Moll et al.
Cell
(1991)
N Iwai et al.
Kidney. Int.
(1990)
D.J Bergsma et al.
J. Biol. Chem.
(1991)
B Haendler et al.
Gene
(1989)

M Tropschug et al.

J. Biol. Chem.

(1988)

J Friedman et al.

Cell

(1991)

P Neri et al.

FEBS Lett.

(1991)

K Wuthrich et al.

FEBS Lett.

(1991)

S.L Schreiber

Science

(1991)

G.R Crabtree

Science

(1989)

R.E Handschumacher et al.

Science

(1984)

W.M Harding et al.

Nature

(1989)

R.F Standaert et al.

Nature

(1990)

J.J Siekierka et al.

Nature

(1989)

N Maki et al.

B.E Bierer et al.

J.F Borel et al.

Immunology

(1977)

J.F Borel et al.

Agents Actions

(1976)

J.E Kay et al.

Immunology

(1983)

N Kumagai et al.

J. Immunol.

(1988)

M.J Tocci et al.

J. Immunol.

(1989)

J.W Lowenthal et al.

J. Immunol.

(1985)

R Cirillo et al.

J. Immunol.

(1990)

A Paulis et al.

J. Immunol.

(1991)

T Hultsch et al.

J. Immunol.

(1990)

S.S Sung et al.

J. Exp. Med.

(1988)

M.K Bijsterbosch et al.

Immunology

(1985)

J.F Elliott et al.

Science

(1984)

M Bickel et al.

G.H Reem et al.

Science

(1983)

A Granelli-Piperno

J. Exp. Med.

(1990)

N Arai et al.

J. Immunol.

(1989)

S.L Cross et al.

Science

(1989)

Cited by (2060)

A novel FK506-loading mesoporous silica nanoparticle homing to lymph nodes for transplant rejection treatment
2024, International Journal of Pharmaceutics
Tacrolimus (FK506) is an effective therapeutic for transplant rejection in clinical practice, primarily inhibiting rejection by suppressing the activation and proliferation of allogeneic T cells in the lymph nodes (LNs). However, conventional administration methods face challenges in directly delivering free FK506 to the LNs. In this study, we introduce a novel LN-targeted delivery system based on mesoporous silica nanoparticles (MSNs-FK506-MECA79). These particles were designed to selectively target high endothelial venules in LNs; this was achieved through surface modification with MECA79 antibodies. Their mean size and zeta potential were 201.18 ± 5.98 nm and − 16.12 ± 0.36 mV, respectively. Our findings showed that MSNs-FK506-MECA79 could accumulate in LNs and increase the local concentration of FK506 from 28.02 ± 7.71 ng/g to 123.81 ± 76.76 ng/g compared with the free FK506 treatment group. Subsequently, the therapeutic efficacy of MSNs-FK506-MECA79 was evaluated in a skin transplantation model. The treatment with MSNs-FK506-MECA79 could lead to a decrease in the infiltration of T cells in the grafts, a reduction in the grade of rejection, and a significant prolongation of survival. Consequently, this study presents a promising strategy for the active LN-targeted delivery of FK506 and improving the immunotherapeutic effects on transplant rejection.
Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2
2024, European Journal of Pharmaceutical Sciences
The upper airways represent the point of entrance from where Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection spreads to the lungs. In the present work, α-tocopheryl-polyethylene-glycol succinate (TPGS) micelles loaded with cyclosporine A (CSA) were developed for nasal administration to prevent or treat the viral infection in the very first phases. The behavior of the micelles in presence of simulated nasal mucus was investigated in terms of stability and mucopenetration rate, evidencing long-term stability and fast diffusion across the glycoproteins matrix. Moreover, the spray characteristics of the micellar formulation and deposition profile in a silicon nasal model were studied using three nasal spray devices. Results allowed to identify the nasal spray pump (BiVax, Aptar) able to provide the wider and uniform deposition of the nasal cavity. The cyclosporine A micelles antiviral activity against SARS-CoV-2 was tested on the Omicron BA.1 variant using Vero E6 cells with protocols simulating treatment before, during and after the infection of the upper airways. Complete viral inactivation was observed for the cyclosporine-loaded micelles while a very low activity was evidenced for the non-formulated drug, suggesting a synergistic activity of the drug and the formulation. In conclusion, this work showed that the developed cyclosporine A-loaded micellar formulations have the potential to be clinically effective against a wide spectrum of coronavirus variants.
Microneedle-mediated transdermal delivery of FK506 for treatment of acute cardiac allograft rejection
2023, Materials and Design
FK506 has been widely used to prevent acute rejection in heart transplantation (HT). However, its strong hydrophobicity, poor bioavailability, high pharmacokinetic variability, and narrow therapeutic window are obstacles to its application in HT. It has been demonstrated that localized and sustained immunosuppressant delivery may be a suitable route for FK506 administration. Hence, the objective of this study was to evaluate the efficacy of a FK506-loaded microneedle (FK506 MN) in the treatment of acute rejection in HT. The physicochemical properties of FK506 MN were evaluated, and it exhibited constant release over the course of at least 9 days with a 94.6 % cumulative release rate. Also, the FK506 MN treatment could successfully alleviate acute rejection and prolong allograft survival compared with the untreated group (mean survival time, 12.33 versus 7.25 days). Furthermore, T cell and macrophage infiltration as well as secretion of IL-2, IL-6 and IFN-γ were dramatically reduced in the FK506 MN group. As expected, no hepatoxicity and nephrotoxicity were observed after the application of FK506 MN. Taken together, FK506 MN based drug delivery system provides a novelty strategy to deliver FK506 in heart transplantation, which may be also suitable for other organ transplantations in the future.
Predictors of relapse and prophylactic management of immune thrombotic thrombocytopenic purpura
2023, Transfusion and Apheresis Science
Current paradigm and treatment options for autoimmune hepatitis
2023, Comprehensive Guide to Hepatitis Advances
Autoimmune hepatitis (AIH) is a chronic autoimmune inflammatory liver disease with a sinister prognosis if untreated. Still, in patients on immunosuppressive treatment, there is increased morbidity and mortality, especially in nonresponders to standard therapy and difficult-to-manage AIH patients. Standard therapy includes prednisolone and azathioprine, while patients with azathioprine intolerance are offered mycophenolate mofetil. Nonresponders may be treated with other immunosuppressive drugs, for example, tacrolimus, ciclosporin, and anti-Tumor Necrosis Factor-α antibodies. Recently also rituximab has been introduced for AIH treatment. However, the evidence for the efficacy of these drugs is primarily based on treatment cohorts and case series from tertiary referral centers. In the present review, we provide the current knowledge regarding standard therapy and suggestions based on the literature for AIH patients being nonresponders to standard therapy and difficult-to-manage AIH patients to standard therapy. Drugs used as second- and third-line therapies are discussed with a suggested algorithm for treatment decisions.
FK506-binding protein, FKBP12, promotes serine utilization and negatively regulates threonine deaminase in fission yeast
2022, iScience
FK506-binding protein with a molecular weight of 12 kDa (FKBP12) is a receptor of the immunosuppressive drugs, FK506 and rapamycin. The physiological functions of FKBP12 remain ambiguous because of its nonessentiality and multifunctionality. Here, we show that FKBP12 promotes the utilization of serine as a nitrogen source and regulates the isoleucine biosynthetic pathway in fission yeast. In screening for small molecules that inhibit serine assimilation, we found that the growth of fission yeast cells in medium supplemented with serine as the sole nitrogen source, but not in glutamate-supplemented medium, was suppressed by FKBP12 inhibitors. Knockout of FKBP12 phenocopied the action of these compounds in serine-supplemented medium. Metabolome analyses and genetic screens identified the threonine deaminase, Tda1, to be regulated downstream of FKBP12. Genetic and biochemical analyses unveiled the negative regulation of Tda1 by FKBP12. Our findings reveal new roles of FKBP12 in amino acid biosynthesis and nitrogen metabolism homeostasis.

View all citing articles on Scopus

View full text

ReviewThe mechanism of action of cyclosporin A and FK506

Abstract

Cell

J. Biol. Chem.

J. Biol. Chem.

Biochim. Biophys. Acta

J. Biol. Chem.

Anal. Biochem.

Cell

Kidney. Int.

J. Biol. Chem.

Gene

J. Biol. Chem.

Cell

FEBS Lett.

FEBS Lett.

Science

Science

Science

Nature

Nature

Nature

Immunology

Agents Actions

Immunology

J. Immunol.

J. Immunol.

J. Immunol.

J. Immunol.

J. Immunol.

J. Immunol.

J. Exp. Med.

Immunology

Science

Science

J. Exp. Med.

J. Immunol.

Science

Review
The mechanism of action of cyclosporin A and FK506